Editor's Corner

Cancer Genetics boosts Medicare coverage for DNA-based cancer Dx

Cancer Genetics isn't making money yet. But the New Jersey developer of DNA-based cancer diagnostics closed out its 2014 second quarter with smaller losses, some strategic acquisitions and a biomarker development partnership with AstraZeneca.

Two tests better than one to spot harmful mold infection

Aspergillus is a mold that infects the respiratory system and can lead to serious illness or death in patients with weakened immune systems. Researchers believe they've found the ideal combination of tests for early, effective diagnosis.

Investors become ambivalent to Biocept's Dx commercialization plans

Biocept recently released its 2014 second-quarter earnings as well as a corresponding update on the company's progress. Its results, which include much higher losses, highlight the molecular diagnostics player's aggressive strategy to achieve commercial success, and how far away it is from actually getting there.

Protagen rolls out autoimmune disease test for research use

Germany's Protagen said it is rolling out its first diagnostic test kit for systemic sclerosis, a rheumatic disease in which autoimmune-induced inflammation, fibrosis and blood vessel disorders can harm a patient's organs and eventually cause death.

Novartis, LabCorp and more back Seventh Sense Biosystems' latest financing

Seventh Sense Biosystems has been quiet these last several months. But now the maker of painless blood collection and diagnostic tech is making some noise, having scored a healthy new round of venture financing.